SHENZHEN, China, Dec. 18 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer,manufacturer and marketer of medical devices worldwide, today announced shareholder resolutions adopted at its annual general meeting of shareholders held in Hong Kong on December 15, 2009.
Mindray shareholders also ratified the appointment of PricewaterhouseCoopers as the company's independent registered public accounting firm for the 2008 and 2009 fiscal years.
Additionally, Mindray shareholders approved an amendment to increase by 6,000,000 the number of shares that may be delivered pursuant to awards granted under the Company's 2006 Employee Share Incentive Plan; the new share limit shall be 21,000,000.
We are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain global headquarters in Shenzhen, China, U.S. headquarters in Mahwah, New Jersey and multiple sales offices in major international markets. From our main manufacturing and engineering base in China and through our worldwide distribution network, we are able to supply internationally a broad range of products across three primary business segments, comprised of patient monitoring and life support products, in-vitro diagnostic products and medical imaging systems. For more information, please visit http://ir.mindray.com .
For investor and media inquiries please contact: In the U.S.: Evan Smith, CFA FD Tel: +1-212-850-5606 Email: [email protected] John Capodanno FD Tel: +1-212-850-5705 Email: [email protected] In China: Cathy Gao Tel: +86-755-2658-2518 Email: [email protected]
SOURCE Mindray Medical International Limited
Subscribe to our Free Newsletters!
Snake antivenom is a medicine used for the treatment of patients suffering from snake envenomation.